-
1
-
-
18844454753
-
Novel histone deacetylase inhibitors in the treatment of thyroid cancer
-
Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA and Mitsiades N: Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 11: 3958-3965, 2005.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3958-3965
-
-
Mitsiades, C.S.1
Poulaki, V.2
McMullan, C.3
Negri, J.4
Fanourakis, G.5
Goudopoulou, A.6
Richon, V.M.7
Marks, P.A.8
Mitsiades, N.9
-
2
-
-
84944909595
-
Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma
-
Raue F and Frank-Raue K: Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma. Recent Results Cancer Res 204: 61-90, 2015.
-
(2015)
Recent Results Cancer Res
, vol.204
, pp. 61-90
-
-
Raue, F.1
Frank-Raue, K.2
-
3
-
-
84923365170
-
Tumorsuppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction
-
Jaskula-Sztul R, Eide J, Tesfazghi S, Dammalapati A, Harrison AD, Yu XM, Scheinebeck C, Winston-McPherson G, Kupcho KR, Robers MB, Hundal AK, Tang W and Chen H: Tumorsuppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction. Mol Cancer Ther 14: 499-512, 2015.
-
(2015)
Mol Cancer Ther
, vol.14
, pp. 499-512
-
-
Jaskula-Sztul, R.1
Eide, J.2
Tesfazghi, S.3
Dammalapati, A.4
Harrison, A.D.5
Yu, X.M.6
Scheinebeck, C.7
Winston-McPherson, G.8
Kupcho, K.R.9
Robers, M.B.10
Hundal, A.K.11
Tang, W.12
Chen, H.13
-
5
-
-
77949490246
-
Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride
-
Adler JT, Hottinger DG, Kunnimalaiyaan M and Chen H: Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J Surg Res 159: 640-644, 2010.
-
(2010)
J Surg Res
, vol.159
, pp. 640-644
-
-
Adler, J.T.1
Hottinger, D.G.2
Kunnimalaiyaan, M.3
Chen, H.4
-
6
-
-
79251524248
-
Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma
-
Biermann K, Biersack HJ, Sabet A and Janzen V: Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma. Semin Nucl Med 41: 139-148, 2011.
-
(2011)
Semin Nucl Med
, vol.41
, pp. 139-148
-
-
Biermann, K.1
Biersack, H.J.2
Sabet, A.3
Janzen, V.4
-
7
-
-
58149387609
-
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma
-
Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M and Shah MH: Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 94: 164-170, 2009.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 164-170
-
-
Woyach, J.A.1
Kloos, R.T.2
Ringel, M.D.3
Arbogast, D.4
Collamore, M.5
Zwiebel, J.A.6
Grever, M.7
Villalona-Calero, M.8
Shah, M.H.9
-
8
-
-
44449130087
-
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells
-
Greenblatt DY, Cayo MA, Adler JT, Ning L, Haymart MR, Kunnimalaiyaan M and Chen H: Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg 247: 1036-1040, 2008.
-
(2008)
Ann Surg
, vol.247
, pp. 1036-1040
-
-
Greenblatt, D.Y.1
Cayo, M.A.2
Adler, J.T.3
Ning, L.4
Haymart, M.R.5
Kunnimalaiyaan, M.6
Chen, H.7
-
9
-
-
84875347365
-
Treatment of advanced medullary thyroid cancer
-
Smit J: Treatment of advanced medullary thyroid cancer. Thyroid Res 6(Suppl 1): S7, 2013.
-
(2013)
Thyroid Res
, vol.6
, pp. S7
-
-
Smit, J.1
-
10
-
-
84866496261
-
Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas
-
Sung TY, Choi SH, Lee JM, Jeong JJ, Kang SW and Chung WY: Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas. J Korean Med Sci 27: 729-735, 2012.
-
(2012)
J Korean Med Sci
, vol.27
, pp. 729-735
-
-
Sung, T.Y.1
Choi, S.H.2
Lee, J.M.3
Jeong, J.J.4
Kang, S.W.5
Chung, W.Y.6
-
11
-
-
84874824354
-
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma
-
Giunti S, Antonelli A, Amorosi A and Santarpia L: Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol 2013: 803171, 2013.
-
(2013)
Int J Endocrinol
, vol.2013
, pp. 803171
-
-
Giunti, S.1
Antonelli, A.2
Amorosi, A.3
Santarpia, L.4
-
12
-
-
33748452681
-
New molecular targeted therapies in thyroid cancer
-
Milano A, Chiofalo MG, Basile M, Salzano de Luna A, Pezzullo L and Caponigro F: New molecular targeted therapies in thyroid cancer. Anticancer Drugs 17: 869-879, 2006.
-
(2006)
Anticancer Drugs
, vol.17
, pp. 869-879
-
-
Milano, A.1
Chiofalo, M.G.2
Basile, M.3
Salzano De Luna, A.4
Pezzullo, L.5
Caponigro, F.6
-
13
-
-
84855960713
-
MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells
-
Brest P, Lassalle S, Hofman V, Bordone O, Gavric Tanga V, Bonnetaud C, Moreilhon C, Rios G, Santini J, Barbry P, Svanborg C, Mograbi B, Mari B and Hofman P: MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer 18: 711-719, 2011.
-
(2011)
Endocr Relat Cancer
, vol.18
, pp. 711-719
-
-
Brest, P.1
Lassalle, S.2
Hofman, V.3
Bordone, O.4
Gavric Tanga, V.5
Bonnetaud, C.6
Moreilhon, C.7
Rios, G.8
Santini, J.9
Barbry, P.10
Svanborg, C.11
Mograbi, B.12
Mari, B.13
Hofman, P.14
-
14
-
-
84893713574
-
Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions
-
Giaginis C, Alexandrou P, Delladetsima I, Giannopoulou I, Patsouris E and Theocharis S: Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biol 35: 61-71, 2014.
-
(2014)
Tumour Biol
, vol.35
, pp. 61-71
-
-
Giaginis, C.1
Alexandrou, P.2
Delladetsima, I.3
Giannopoulou, I.4
Patsouris, E.5
Theocharis, S.6
-
15
-
-
84931357766
-
Histone deacetylase (HDAC) inhibitors: Current evidence for therapeutic activities in pancreatic cancer
-
Damaskos C, Karatzas T, Nikolidakis L, Kostakis ID, Karamaroudis S, Boutsikos G, Damaskou Z, Kostakis A and Kouraklis G: Histone deacetylase (HDAC) inhibitors: Current evidence for therapeutic activities in pancreatic cancer. Anticancer Res 35: 3129-3136, 2015.
-
(2015)
Anticancer Res
, vol.35
, pp. 3129-3136
-
-
Damaskos, C.1
Karatzas, T.2
Nikolidakis, L.3
Kostakis, I.D.4
Karamaroudis, S.5
Boutsikos, G.6
Damaskou, Z.7
Kostakis, A.8
Kouraklis, G.9
-
16
-
-
84855471990
-
HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications
-
Khan O and La Thangue NB: HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94, 2012.
-
(2012)
Immunol Cell Biol
, vol.90
, pp. 85-94
-
-
Khan, O.1
La Thangue, N.B.2
-
17
-
-
70349100446
-
Histone deacetylase inhibitors: Current status and overview of recent clinical trials
-
Ma X, Ezzeldin HH and Diasio RB: Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69: 1911-1934, 2009.
-
(2009)
Drugs
, vol.69
, pp. 1911-1934
-
-
Ma, X.1
Ezzeldin, H.H.2
Diasio, R.B.3
-
18
-
-
77649171884
-
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
-
Tan J, Cang S, Ma Y, Petrillo RL and Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5, 2010.
-
(2010)
J Hematol Oncol
, vol.3
, pp. 5
-
-
Tan, J.1
Cang, S.2
Ma, Y.3
Petrillo, R.L.4
Liu, D.5
-
19
-
-
84959120824
-
Histone deacetylase (HDAC)-1,-2,-4 and-6 expression in human pancreatic adenocarcinoma: Associations with clinicopathological parameters, tumor proliferative capacity and patients' survival
-
Giaginis C, Damaskos C, Koutsounas I, Zizi-Serbetzoglou A, Tsoukalas N, Patsouris E, Kouraklis G and Theocharis S: Histone deacetylase (HDAC)-1,-2,-4 and-6 expression in human pancreatic adenocarcinoma: Associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. BMC Gastroenterol 15: 148, 2015.
-
(2015)
BMC Gastroenterol
, vol.15
, pp. 148
-
-
Giaginis, C.1
Damaskos, C.2
Koutsounas, I.3
Zizi-Serbetzoglou, A.4
Tsoukalas, N.5
Patsouris, E.6
Kouraklis, G.7
Theocharis, S.8
-
20
-
-
73949128107
-
Histone deacetylase inhibitors in cancer therapy
-
Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5459-5468
-
-
Lane, A.A.1
Chabner, B.A.2
-
21
-
-
81555228390
-
Belinostat: Clinical applications in solid tumors and lymphoma
-
Molife LR and de Bono JS: Belinostat: Clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs 20: 1723-1732, 2011.
-
(2011)
Expert Opin Investig Drugs
, vol.20
, pp. 1723-1732
-
-
Molife, L.R.1
De Bono, J.S.2
-
22
-
-
84991832873
-
-
National Institutes of Health (NIH), Clinical Trials
-
National Institutes of Health (NIH), Clinical Trials. Available at: http://www.clinicaltrials.gov.
-
-
-
-
23
-
-
85013006897
-
Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA)
-
Xu Y, Xu D, Zhu SJ, Ye B, Dong JD, Zhang YL and Zhang Y: Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA). Int J Clin Exp Pathol 8: 8291-8297, 2015.
-
(2015)
Int J Clin Exp Pathol
, vol.8
, pp. 8291-8297
-
-
Xu, Y.1
Xu, D.2
Zhu, S.J.3
Ye, B.4
Dong, J.D.5
Zhang, Y.L.6
Zhang, Y.7
-
24
-
-
35448983934
-
Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC)
-
Provenzano MJ, Fitzgerald MP, Krager K and Domann FE: Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg 137: 722-728, 2007.
-
(2007)
Otolaryngol Head Neck Surg
, vol.137
, pp. 722-728
-
-
Provenzano, M.J.1
Fitzgerald, M.P.2
Krager, K.3
Domann, F.E.4
-
25
-
-
68649119641
-
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336)
-
Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, Wong L, Ward JH, Abbruzzese JL and Blanke CD: Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336). Invest New Drugs 27: 469-475, 2009.
-
(2009)
Invest New Drugs
, vol.27
, pp. 469-475
-
-
Whitehead, R.P.1
Rankin, C.2
Hoff, P.M.3
Gold, P.J.4
Billingsley, K.G.5
Chapman, R.A.6
Wong, L.7
Ward, J.H.8
Abbruzzese, J.L.9
Blanke, C.D.10
-
26
-
-
84885400899
-
Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment
-
Lin SF, Lin JD, Chou TC, Huang YY and Wong RJ: Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS One 8: e77684, 2013.
-
(2013)
PLoS One
, vol.8
, pp. e77684
-
-
Lin, S.F.1
Lin, J.D.2
Chou, T.C.3
Huang, Y.Y.4
Wong, R.J.5
-
27
-
-
35448983934
-
Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC)
-
Provenzano MJ, Fitzgerald MP and Domann FE: Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg 137: 722-728, 2007.
-
(2007)
Otolaryngol Head Neck Surg
, vol.137
, pp. 722-728
-
-
Provenzano, M.J.1
Fitzgerald, M.P.2
Domann, F.E.3
-
28
-
-
0038676409
-
Inhibition of histone deacetylase activity by butyrate
-
Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr 133(7 Suppl): 2485S-2493S, 2003.
-
(2003)
J Nutr
, vol.133
, Issue.7
, pp. 2485S-2493S
-
-
Davie, J.R.1
-
29
-
-
0032500865
-
Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies
-
Pouillart PR: Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Life sciences 63: 1739-1760, 1998.
-
(1998)
Life Sciences
, vol.63
, pp. 1739-1760
-
-
Pouillart, P.R.1
-
30
-
-
79960087121
-
Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells
-
Dong X, Korch C and Meinkoth JL: Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells. Endocr Relat Cancer 18: 301-10, 2011.
-
(2011)
Endocr Relat Cancer
, vol.18
, pp. 301-310
-
-
Dong, X.1
Korch, C.2
Meinkoth, J.L.3
-
31
-
-
79955801797
-
Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells
-
Yuan GB, Kuang AR, Fan Q, Yu LB and Mi YX; Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells. Chin J Cancer 29: 379-84, 2010.
-
(2010)
Chin J Cancer
, vol.29
, pp. 379-384
-
-
Yuan, G.B.1
Kuang, A.R.2
Fan, Q.3
Yu, L.B.4
Mi, Y.X.5
-
32
-
-
0036910932
-
Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor
-
Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY and Clark OH: Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132: 984-90, 2002.
-
(2002)
Surgery
, vol.132
, pp. 984-990
-
-
Zarnegar, R.1
Brunaud, L.2
Kanauchi, H.3
Wong, M.4
Fung, M.5
Ginzinger, D.6
Duh, Q.Y.7
Clark, O.H.8
-
33
-
-
84903612130
-
Histone deacetylase inhibitors in cancer therapy A review
-
Hrabeta J, Stiborova M, Adam V, Kizek R and Eckschlager T: Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158: 161-169, 2014.
-
(2014)
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
, vol.158
, pp. 161-169
-
-
Hrabeta, J.1
Stiborova, M.2
Adam, V.3
Kizek, R.4
Eckschlager, T.5
-
34
-
-
50049117726
-
Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma
-
Ning L, Jaskula-Sztul R, Kunnimalaiyaan M and Chen H: Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. Ann Surg Oncol 15: 2600-2605, 2008.
-
(2008)
Ann Surg Oncol
, vol.15
, pp. 2600-2605
-
-
Ning, L.1
Jaskula-Sztul, R.2
Kunnimalaiyaan, M.3
Chen, H.4
-
35
-
-
84991825469
-
Histone deacetylase inhibitors: Updated studies in various epigenetic-related diseases
-
Zwergel C, Stazi G, Valente S and Mai A: Histone deacetylase inhibitors: Updated studies in various epigenetic-related diseases. J Clin Epigenet 2: 1, 2016.
-
(2016)
J Clin Epigenet
, vol.2
, pp. 1
-
-
Zwergel, C.1
Stazi, G.2
Valente, S.3
Mai, A.4
-
36
-
-
79952932076
-
Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs
-
Kim HJ and Bae SC: Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3: 166-179, 2011.
-
(2011)
Am J Transl Res
, vol.3
, pp. 166-179
-
-
Kim, H.J.1
Bae, S.C.2
-
37
-
-
79251559363
-
Valproate-doxorubicin: Promising therapy for progressing mesothelioma A phase II study
-
Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, Richez M, Bonduelle Y, Meert AP, Dhalluin X, Leclercq N, Paesmans M, Willems L and Sculier JP: Valproate-doxorubicin: Promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 37: 129-135, 2011.
-
(2011)
Eur Respir J
, vol.37
, pp. 129-135
-
-
Scherpereel, A.1
Berghmans, T.2
Lafitte, J.J.3
Colinet, B.4
Richez, M.5
Bonduelle, Y.6
Meert, A.P.7
Dhalluin, X.8
Leclercq, N.9
Paesmans, M.10
Willems, L.11
Sculier, J.P.12
-
38
-
-
73849114072
-
Histone deacetylase inhibitors induce thyroid cancer specific apoptosis through proteasomedependent inhibition of TRAIL degradation
-
Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, Altucci L and Fusco A: Histone deacetylase inhibitors induce thyroid cancer specific apoptosis through proteasomedependent inhibition of TRAIL degradation. Oncogene 29: 105-116, 2010.
-
(2010)
Oncogene
, vol.29
, pp. 105-116
-
-
Borbone, E.1
Berlingieri, M.T.2
De Bellis, F.3
Nebbioso, A.4
Chiappetta, G.5
Mai, A.6
Altucci, L.7
Fusco, A.8
-
39
-
-
73149115248
-
Targeting the RET pathway in thyroid cancer
-
Wells SA Jr. and Santoro M: Targeting the RET pathway in thyroid cancer. Clin Cancer Res 15: 7119-7123, 2009.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7119-7123
-
-
Wells, S.A.1
Santoro, M.2
-
40
-
-
17144379329
-
Familial medullary thyroid cancer clinical aspects and prognosis
-
Hyer SL, Newbold K and Harmer C: Familial medullary thyroid cancer clinical aspects and prognosis. Eur J Surg Oncol 31: 415-419, 2005.
-
(2005)
Eur J Surg Oncol
, vol.31
, pp. 415-419
-
-
Hyer, S.L.1
Newbold, K.2
Harmer, C.3
-
41
-
-
77953365033
-
Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer
-
Cook M, Yu XM and Chen H: Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer. Am J Transl Res 2: 119-125, 2010.
-
(2010)
Am J Transl Res
, vol.2
, pp. 119-125
-
-
Cook, M.1
Yu, X.M.2
Chen, H.3
|